Drugs / Fampridine-SR
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 33 trials | ||||||
| Phase 3 | NCT00649792 | Aug 2007 → Jan 2011 | multiple sclerosis | Acorda Therapeutics | Completed | No outcome recorded |
| Phase 3 | NCT00648908 | Jun 2006 → Jan 2011 | multiple sclerosis | Acorda Therapeutics | Completed | No outcome recorded |
| Phase 3 | NCT00654927 | Nov 2003 → Jan 2011 | multiple sclerosis | Acorda Therapeutics | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT00483652 Comparator | May 2007 → Feb 2008 | multiple sclerosis | Acorda Therapeutics | Completed | No outcome recorded |
| Phase 3 | NCT00041717 Comparator | Jul 2002 → Feb 2004 | spinal cord injury | Acorda Therapeutics | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fampridine-SR | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00483652 ↗ |
| Route | Oral | “Oral Fampridine-SR” NCT00041717 ↗ |